The identification of actionable tumor antigens is indispensable for the development of
several cancer immunotherapies, including T cell receptor–transduced T cells and patient …

Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …

Prediction of HLA epitopes is important for the development of cancer immunotherapies and
vaccines. However, current prediction algorithms have limited predictive power, in part …

The recent development of machine learning methods to identify peptides in complex mass
spectrometric data constitutes a major breakthrough in proteomics. Longstanding methods …

The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …

Characterizing the human leukocyte antigen (HLA) bound ligandome by mass spectrometry
(MS) holds great promise for developing vaccines and drugs for immune-oncology. Still, the …

Tumor-associated epitopes presented on MHC-I that can activate the immune system
against cancer cells are typically identified from annotated protein-coding regions of the …

Immune-checkpoint inhibition provides an unmatched level of durable clinical efficacy in
various malignancies. Such therapies promote the activation of antigen-specific T cells …

Throughout the body, T cells monitor MHC-bound ligands expressed on the surface of
essentially all cell types. MHC ligands that trigger a T cell immune response are referred to …

The ability of mammals to mount adaptive immune responses culminating with the
establishment of immunological memory is predicated on the ability of the mature T cell …